Founded in 2008, we are a privately-held biotech company with two primary areas of business: Pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. Our focus is the metabolic space (obesity, diabetes, NASH and gastrointestinal diseases), where we specialize in in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, imaging, stereology, NGS (next generation sequencing), bioinformatics and ex vivo assays. Gubra is an abbreviation for GUt and BRAin, the original key focus areas of our research and expertise. We work with some of the most interesting and loyal partners and customer from across the world within big pharma, biotech and academia. Through a constant focus on high quality, scientific excellence, speed and solid teamwork, we have established ourselves as a highly professional and competent partner in the market.